Aurobindo Pharma Share Price Target 2026: Brokerage firm Nuvama has delivered a bullish outlook on Aurobindo Pharma’s stock after the company said its arm Aurobindo Pharma USA, Inc had received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC.
At 9:29 AM today, shares of Aurobindo Pharma were trading at Rs 1524.00, up 2.12 per cent from the previous close on the BSE.
Created with AI. Errors are possibleThe brokerage cited that Lannett acquisition is projected to hit a USD 500 million revenue scale, boosted by a robust respiratory portfolio featuring the upcoming launch of gAdvair.
– Aurobindo is pivoting from a high-investment phase into higher-value, complex modalities, while maintaining steady growth across its European and RoW footprints.
– Primary long-term capital allocations include the Pen-G project, various oral/injectable facilities, Lannett, and biosimilars.
– A Rs 10bn CMO Unit I is also targeted for an FY29E launch.
– Domestic Pen-G facility is slated to achieve an initial 60-80% utilization rate, triggering ~Rs. 7bn in revenue, which includes an estimated Rs. 2.4bn PLI incentive payout.
– The company’s first novel asset, Adquey, is scheduled to launch within the next few months, with peak sales potential modeled at USD 250-300mn.
– The core European business to scale smoothly to EUR 1.2bn by FY28E.
– China business is structurally turning around from a loss-making entity in FY26 to a projected ~USD 10mn EBITDA in FY27E.
– The high margin biosimilars and CMO lines are expected to drive meaningful financial scale from FY29E.
– Forecasted a revenue and PAT CAGR of 15% and 24% respectively, alongside a ~200bp RoCE by FY28E.
Aurobindo Pharma Q4 results
Aurobindo Pharma Ltd has reported a 2 per cent rise in consolidated profit after tax to Rs 920.84 crore in the fourth quarter ended March 31.
The company had posted a consolidated profit after tax (PAT) of Rs 902.83 crore in the corresponding quarter of the previous fiscal, Aurobindo Pharma Ltd said in a regulatory filing.
Its consolidated total revenue from operations in the fourth quarter stood at Rs 8,853.34 crore against Rs 8,382.12 crore in the year-ago period, it added.
The company’s total expenses in the quarter under review were higher at Rs 7,677.34 crore compared to Rs 7,149.65 crore in the year-ago period, the company said.
For FY26, consolidated PAT was Rs 3,502.97 crore against Rs 3,483.57 crore in FY25.
Its consolidated total revenue from operations in FY26 stood at Rs 33,653.08 crore against Rs 31,723.73 crore in FY25.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions.)
